Vortioxetine in the treatment of adult patients with major depressive disorder: A meta-analysis of randomized double-blind controlled trials

BMC Psychiatry

Volumn 14, Issue 1, 2014, Pages

  Berhan, Asres ^a   Barker, Alex ^b  

^a HAWASSA UNIVERSITY   (Ethiopia)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Depression symptoms; Major depressive disorder; Meta analysis; Serotonin; Vortioxetine

Indexed keywords

DULOXETINE; PLACEBO; VENLAFAXINE; VORTIOXETINE; ANTIDEPRESSANT AGENT; PIPERAZINE DERIVATIVE; SEROTONIN 7 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SULFIDE;

ADULT; ARTICLE; DRUG EFFICACY; DRUG SAFETY; HAMILTON SCALE; HUMAN; HYPERHIDROSIS; MAJOR DEPRESSION; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT DURATION; DEPRESSIVE DISORDER, MAJOR; DOUBLE BLIND PROCEDURE; METABOLISM;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; HUMANS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN RECEPTOR AGONISTS; SULFIDES;

EID: 84909988112     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-014-0276-x     Document Type: Article

References (24)

1. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 2014, 19(2):121-133. 10.1017/S1092852913000540, 23903233.
2. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009, 29:259-266. 10.1097/JCP.0b013e3181a5233f, 19440080.
3. Ranjbar S, Pai NB, Deng C. The Association of Antidepressant Medication and Body Weight Gain. OJHAS 2013, 12(1):1-9.
4. Wu C, Gau SS, Lai M. Long-term antidepressant use and the risk of type 2 diabetes mellitus: a population-based, nested case-control study in Taiwan [CME]. J Clin Psychiatry 2014, 75:31-38. 10.4088/JCP.13m08421, 24502860.
5. Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 2007, 9(1):47-59. 17506225.
6. Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A, Stensbøl T. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011, 54(9):3206-3221. 10.1021/jm101459g, 21486038.
7. Mork A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, Sanchez C, Fischer CW, Liebenberg N, Wegener G, Bundgaard C, Hogg S, Bang-Andersen B, Stensbol TB. Pharmacological effects of Lu AA21004: A novel multimodal compound for the treatment of major depressive disorder. J PHarmacol Exp Ther 2012, 340:666-675. 10.1124/jpet.111.189068, 22171087.
8. Areberg J, Søgaard B, Højer A. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Basic Clin Pharmacol 2012, 111:198-205.
9. Chen G, Lee R, Højer A, Buchbjerg JK, Serenko M, Zhao Z. Pharmacokinetic drug interactions involving Vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig 2013, 33:727-736. 10.1007/s40261-013-0117-6, 23975654.
10. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychoph 2012, 15:589-600. 10.1017/S1461145711001027.
11. Katona C, Hensen T, Olsen, Christina, Kurre, Olsen A, Christina A, Kurre A. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int J Neuropsychoph 2012, 27:215-223.
12. Boulenger J, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 2014, 29(3):138-149. 10.1097/YIC.0000000000000018, 24257717.
13. Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerablity of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 2012, 73:953-959. 10.4088/JCP.11m07470, 22901346.
14. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharm 2012, 27:215-223.
15. Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychoph 2013, 16:313-321. 10.1017/S1461145712000727.
16. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin 2013, 29:217-226. 10.1185/03007995.2012.761600, 23252878.
17. Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw 2012, 49:5.
18. Alam MY, Jacobsen PL, Chen Y, Serenko M, Mahableshwarkar AR. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int J Neuropsychoph 2014, 29:36-44.
19. Baldwin DS, Thomas H, Ioana F. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin 2012, 28(10):1717-1724. 10.1185/03007995.2012.725035, 22978748.
20. Machado-Vieira R, Baumann J, Wheeler-Castillo C, Latov D, Henter Ioline D, Salvadore G, Zarate J, Carlos A. The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals 2010, 3:19-41. 10.3390/ph3010019.
21. Fanelli D. How many scientists fabricate and falsify research? a systematic review and meta-analysis of survey data. PLoS ONE 2009, 4(5):4:e5738. 10.1371/journal.pone.0005738.
22. Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. Int J Clin Pract 2014, 68:60-82. 10.1111/ijcp.12350, 24165478.
23. Theunissen EL, Street D, Højer A, Vermeeren A, Van Oers A, Ramaekers JG. A randomized trial on the acute and steady-state effects of a new antidepressant, Vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther 2013, 93:493-501. 10.1038/clpt.2013.39, 23588319.
24. Walker E, Hernandez AV, Kattan MW. Meta-analysis: its strengths and limitations. Clev Clin J Med 2008, 75:431-439. 10.3949/ccjm.75.6.431.